Barclays PLC Has $1.20 Million Stake in Iradimed Corporation (NASDAQ:IRMD)

Barclays PLC lifted its stake in shares of Iradimed Corporation (NASDAQ:IRMD) by 113.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,774 shares of the medical equipment provider’s stock after purchasing an additional 12,657 shares during the quarter. Barclays PLC owned 0.19% of Iradimed worth $1,196,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. grew its stake in shares of Iradimed by 1.9% during the third quarter. Jacobs Levy Equity Management Inc. now owns 24,779 shares of the medical equipment provider’s stock worth $1,246,000 after buying an additional 472 shares during the last quarter. ClariVest Asset Management LLC grew its position in Iradimed by 2.9% during the 2nd quarter. ClariVest Asset Management LLC now owns 17,666 shares of the medical equipment provider’s stock worth $776,000 after acquiring an additional 494 shares during the last quarter. Huntington National Bank increased its holdings in Iradimed by 51.3% in the 3rd quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider’s stock worth $75,000 after purchasing an additional 504 shares in the last quarter. Cim LLC raised its position in Iradimed by 5.9% in the second quarter. Cim LLC now owns 10,089 shares of the medical equipment provider’s stock valued at $464,000 after purchasing an additional 561 shares during the last quarter. Finally, Kings Path Partners LLC boosted its stake in shares of Iradimed by 2.3% during the third quarter. Kings Path Partners LLC now owns 24,570 shares of the medical equipment provider’s stock valued at $1,236,000 after purchasing an additional 562 shares in the last quarter. 92.34% of the stock is currently owned by institutional investors and hedge funds.

Iradimed Trading Down 0.6 %

NASDAQ:IRMD opened at $54.67 on Monday. The stock’s 50-day moving average is $53.30 and its 200-day moving average is $48.77. Iradimed Corporation has a 1-year low of $40.18 and a 1-year high of $57.95. The stock has a market cap of $692.67 million, a P/E ratio of 37.45 and a beta of 0.82.

Iradimed Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, November 25th. Shareholders of record on Friday, November 15th were given a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 1.10%. The ex-dividend date of this dividend was Friday, November 15th. Iradimed’s dividend payout ratio (DPR) is currently 41.10%.

Insider Buying and Selling at Iradimed

In other Iradimed news, CFO John Glenn sold 2,500 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the sale, the chief financial officer now owns 4,383 shares in the company, valued at approximately $237,470.94. The trade was a 36.32 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 37.10% of the company’s stock.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.